The stable knockdown of the SWI/SNF catalytic subunits BRG1 and BRM in lung cancer and head/neck cancer cells can enhance the sensitivity of cells to cisplatin because the downregulation of BRG1 and BRM hinders the repair of DNA intrastrand adducts and interstrand crosslinks (ICLs) [245]. Here, SMARCA2 is linked to lung cancer.